Continued therapy with adalimumab in patients with nonradiographic axial spondyloarthritis was associated with better maintenance of remission than withdrawing adalimumab in the ABILITY-3 study. Of the 305 enrolled patients who achieved sustained remission after 28 weeks of open-label adalimumab treatment (40 mg subcutaneously every other week), 152 were randomly assigned to continue adalimumab treatment and 153 received placebo instead. At the end of the 40-week double-blind period, more patients in the placebo group had experienced a flare than in the adalimumab group (70% versus 47%).